Evoke Pharma INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
EVOK
Evoke Pharma INCMorgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have filed an amended Schedule 13G indicating their beneficial ownership of Evoke Pharma Inc. common stock has fallen below the 5% threshold.
EVOK
Evoke Pharma INCMorgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have reported a 10.5% beneficial ownership stake in Evoke Pharma Inc. common stock.
EVOK
Evoke Pharma INCLaurence W. Lytton has filed an amended Schedule 13G, reporting beneficial ownership of 3.9% of Evoke Pharma Inc's common stock, primarily through warrants, as a passive investor.
EVOK
Evoke Pharma INCSCHEDULE 13G/A: Bleichroeder LP Discloses 9.99% Stake in Evoke Pharma, Inc. Through Common Shares and Warrants
Bleichroeder LP, along with Bleichroeder Holdings LLC and Andrew Gundlach, has filed an amended Schedule 13G disclosing a 9.99% beneficial ownership stake in Evoke Pharma, Inc., comprising common shares and warrants, subject to a beneficial ownership limitation.
EVOK
Evoke Pharma INCBleichroeder LP, along with Bleichroeder Holdings LLC and Andrew Gundlach, has filed an amended Schedule 13G disclosing a 9.99% beneficial ownership stake in Evoke Pharma, Inc., primarily held through The Denise and Michael Kellen Foundation.